The state of Virginia currently has 17 active clinical trials seeking participants for Pancreatic Cancer research studies. These trials are conducted in various cities, including Richmond, Charlottesville, Norfolk and Fairfax.
Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
NCT06479239
Recruiting
The purpose of this study is to understand the safety and estimate the efficacy of combining anti-cluster of differentiation 3 (CD3) x anti-Epidermal Growth Factor Receptor (EGFR) bispecific antibody fresh peripheral blood mononuclear cells (EGFR FPBMC) for patients with relapsed and/or refractory pancreas cancer. Participants receive 8 weekly doses and then 8 more doses every 2 weeks of EGFR FPBMC by intravenous infusion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Pancreas Cancer, Pancreatic Cancer
Register for Updates
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432
Recruiting
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: NEXT Oncology, Fairfax, Virginia
Conditions: Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer, Platinum-resistant Ovarian Cancer (PROC)
Register for Updates
Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
NCT02598349
Recruiting
The prognosis for patients with localized pancreatic adenocarcinoma who are not surgical candidates is poor. Patients characterized as having "borderline resectable" disease treated with preoperative chemo-radiotherapy fair somewhat better - although many of these patients are not converted to resectability. It may be argued that intensification of local and regional therapy might 1.) Increase the share of patients able to undergo curative surgery and 2.) Improve the local disease control interv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: Inova Schar Cancer Institute, Fairfax, Virginia
Conditions: Pancreatic Cancer
Register for Updates
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
NCT02843945
Recruiting
Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia
Conditions: Pancreatic Cancer
Register for Updates
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
NCT05163028
Recruiting
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic profile.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
Register for Updates